Business Context and Reporting Period
This Form 8-K is a current report filed by Anthem, Inc. (now Elevance Health, Inc.) on June 13, 2018. The filing serves as a Regulation FD disclosure regarding upcoming investor communications scheduled between June 13, 2018, and June 29, 2018.
Key Financial Metrics
The filing does not report historical revenue, profit, cash flow, margins, debt, or liquidity figures for a specific reporting period. It focuses exclusively on forward-looking earnings guidance.
Material Changes and Guidance
During the specified investor meetings, management intends to reaffirm the full-year 2018 net income guidance:
- Reported Net Income: Greater than $14.12 per share.
- Adjustments: Includes approximately $1.18 per share of net negative adjustment items.
- Adjusted Net Income: Greater than $15.30 per share (excluding the aforementioned adjustment items).
The guidance explicitly states it does not include any adjustment items beyond those reported in the Company's first quarter 2018 earnings release.
Risks and Contingencies
The document contains extensive forward-looking statements subject to risks and uncertainties. Key risks identified include:
- Regulatory Environment: Changes in the Affordable Care Act (ACA), Medicare, and Medicaid programs, including CMS Star ratings and funding risks.
- Operational and Market Risks: Healthcare cost trends, provider contracting, premium rate approvals, enrollment reductions, and competitive pricing pressures.
- Legal and Litigation: Ongoing litigation with Cigna Corporation regarding their merger agreement, including potential termination fees and damages.
- Financial and Strategic Risks: Substantial outstanding indebtedness, potential downgrades in financial strength ratings, and risks related to the Express Scripts, Inc. pharmacy benefit management agreement.
- Other Risks: Data breaches, public health epidemics, and general economic downturns.
Investor Verification Checklist
- Verify the specific nature and magnitude of the $1.18 per share negative adjustment items referenced in the Q1 2018 earnings release.
- Monitor the status and potential financial impact of the litigation between Anthem and Cigna Corporation.
- Review upcoming regulatory changes affecting the ACA, Medicare, and Medicaid reimbursement rates.
- Assess the Company's ability to maintain CMS Star ratings and secure premium rate approvals in key markets.
- Confirm the terms and compliance status of the Express Scripts, Inc. pharmacy benefit management agreement.